Clinical trials
Myocardial Infarction trials in Portugal
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 3 |
| 2013 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 4 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv | 2 |
| AstraZeneca | 2 |
| Sanofi | 2 |
| Universidade do Porto | 2 |
| Boehringer Ingelheim | 1 |
| Boston Medical Center | 1 |
| CSL Behring | 1 |
| CardioKinetix, Inc | 1 |
| Fondazione Don Carlo Gnocchi ETS | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myocardial Infarction | 25 |
| Stroke | 8 |
| Coronary Artery Disease | 6 |
| Cardiovascular Diseases | 5 |
| Acute Coronary Syndrome | 4 |
| Diabetes Mellitus | 4 |
| Angina, Unstable | 3 |
| Dyslipidemias | 3 |
| Heart Failure | 3 |
| Diabetes Mellitus, Type 2 | 2 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.